文献速递技术与安全MR

钆基对比剂安全性更新:来自AJR对比剂专辑

Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media.
PubMed 文献 · AJR Am J Roentgenol · 2023-11-15

钆增强MRI已应用超过35年,钆基对比剂总体安全但存在四类安全性问题:急性类过敏反应、肾源性系统性纤维化(NSF)、钆沉积及与钆暴露相关的症状。文章总结市售钆基对比剂的最新安全性证据,讨论ACR NSF分类更新,并描述强化监管决策所需证据的方法。

要点

  • 急性反应远少于碘对比剂,但仍可发生严重反应。
  • NSF见于肾衰竭患者使用ACR I组钆剂后,II组和III组风险较低。
  • 所有钆剂均可沉积,线性剂沉积多于大环剂,但迄今无不良生物学或临床效应证据。

核心结论

  • 钆基对比剂总体非常安全,但需关注急性类过敏反应、NSF、钆沉积及与钆暴露相关症状四类安全性问题。
  • NSF主要与ACR I组钆剂在肾衰竭患者中的使用相关,II组和III组钆剂风险较低,其使用已使NSF基本消除。
  • 所有钆剂均可发生钆沉积,线性剂似乎比大环剂沉积更多,但迄今无数据显示钆沉积导致不良生物学或临床效应,即使肾功能正常者亦然。

研究设计与样本

  • 本文为综述,总结市售钆基对比剂的最新安全性证据,重点关注新型对比剂,并讨论ACR NSF钆剂安全分类更新及强化监管决策证据的方法。

诊断标准与关键数值

  • ACR将钆基对比剂分为I组、II组和III组,I组与NSF相关,II组和III组被认为风险较低。
  • 急性反应发生率远低于碘对比剂,但严重反应虽罕见仍可发生。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Since its introduction more than 35 years ago, gadolinium-enhanced MRI has fundamentally changed medical practice. Although extraordinarily safe, gadolinium-based contrast agents (GBCAs) may have side effects. Four distinct safety considerations include acute allergiclike reactions, nephrogenic systemic fibrosis (NSF), gadolinium deposition, and symptoms associated with gadolinium exposure. Acute reactions after GBCA administration are uncommon-far less than with iodinated contrast agents-and, although rare, serious reactions can occur. NSF is a rare but serious sclerodermalike condition occurring in patients with kidney failure after exposure to American College of Radiology (ACR) group I GBCAs. Group II and III GBCAs are considered lower risk, and, through their use, NSF has largely been eliminated. Unrelated to NSF, retention of trace amounts of gadolinium in the brain and other organs has been recognized for over a decade. Deposition occurs with all agents, although linear agents appear to deposit more than macrocyclic agents. Importantly, to date, no data show any adverse biologic or clinical effects from gadolinium deposition, even with normal kidney function. This article summarizes the latest safety evidence of commercially available GBCAs with a focus on new agents, discusses updates to the ACR NSF GBCA safety classifications, and describes approaches for strengthening the evidence needed for regulatory decisions.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Starekova J, Pirasteh A, Reeder SB, et al. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media. AJR Am J Roentgenol. 2023. PMID: 37850581. doi:10.2214/AJR.23.30036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。